Skip to main content
SpringerLink
Log in

Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin

Rationale for Use in Solid Tumours

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Polyethylene glycol (PEG)-coated (pegylated; Stealth®) liposomes are stable, long-circulating drug carriers useful for delivering doxorubicin to the sites of solid tumours. Compared with conventional liposomes, pegylated liposomes are less extensively taken up by cells of the reticuloendothelial system (RES) and have a reduced tendency to leak drug while in circulation.

The pharmacokinetics of PEG-liposome encapsulated doxorubicin are characterised by an extremely long circulating half-life, slow plasma clearance and a reduced volume of distribution compared with conventional liposomal doxorubicin or free doxorubicin.

The long circulation and ability of pegylated liposomes to extravasate through ‘leaky’ tumour vasculature results in localisation of doxorubicin in tumour tissue. In a number of animal and human tumours, including breast, prostate, pancreatic and ovarian xenografts, pegylated liposomal doxorubicin produced higher intratumoural drug concentrations and better therapeutic responses than equivalent doses of conventional (nonpegylated)-liposome encapsulated doxorubicin or free doxorubicin.

Low peak plasma concentrations of free doxorubicin after administration of pegylated liposomal doxorubicin and the reduced tendency of the liposomal drug to accumulate in myocardium suggest that a reduction in cardiac toxicity compared with free doxorubicin may be observed.

Thus, the rationale for the use of pegylated liposomal doxorubicin in solid tumours may be summarised as follows: change in the toxicity profile with a decrease in acute adverse effects (such as nausea and vomiting) and reduced incidence of alopecia, greater activity in highly angiogenic tumours (such as Kaposi’s sarcoma) and effective treatment of tumours moderately sensitive to doxorubicin (such as breast and ovarian carcinomas), with the possibility of increased tumour response because of enhanced drug accumulation. In addition, although no comparative study yet exists, there is a suggestion from early human studies with pegylated liposomal doxorubicin that cardiotoxicity may be reduced compared with the free drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Working PK, Dayan AD. Pharmacological-toxicological expert report: Caelyx™(Stealth® liposomal doxorubicin HCl). Hum Exper Toxicol 1996; 15: 752–85

    Article  Google Scholar 

  2. Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilised liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991; 1070: 187–92

    Article  PubMed  CAS  Google Scholar 

  3. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10(5): 703–8

    Article  PubMed  CAS  Google Scholar 

  4. Gabizon A, Chemla M, Tzemach A, et al. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Targeting 1996; 3: 391–8

    Article  CAS  Google Scholar 

  5. Unezaki S, Maruyama K, Ishida O, et al. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly (ethylene glycol). Int J Pharm 1995; 126: 41–8

    Article  CAS  Google Scholar 

  6. Gabizon AA. Liposomal anthracyclines. New Drug Ther 1994; 8(2): 431–50

    CAS  Google Scholar 

  7. Schüller J, Czejka M, Bandak S, et al. Comparison of pharmacokinetics (PK) of free and liposome encapsulated doxorubicin in advanced cancer patients [abstract no. 642]. Onkologie 1995; 18Suppl. 2: 184

    Google Scholar 

  8. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996; 36: 55–63

    PubMed  CAS  Google Scholar 

  9. Amantea MA, Forrest A, DuMond C, et al. Population PK and PD of liposomal doxorubicin (LD) in HIV-infected patients (pts) with Kaposi’s sarcoma (KS) [abstract no. PI-82A]. Am Soc Clin Pharmacol Ther 1995; 57(2): 155

    Google Scholar 

  10. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–92

    PubMed  CAS  Google Scholar 

  11. Cowens JW, Creaven PJ, Greco WR, et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796–2802

    PubMed  CAS  Google Scholar 

  12. Gabizon A, Goren D, Horowitz AT, et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997; 24: 337–344

    Article  CAS  Google Scholar 

  13. Lopez-Berenstein G, Kasi L, Rosenblum MG, et al. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res 1984; 44: 375

    Google Scholar 

  14. Harrington KJ, Gooden CSR, Mohammeddtaghi S, et al. Biodistribution and pharmacokinetics of In-111-labeled Stealth liposomes in patients with solid tumours [abstract no. 1511]. Proc Am Soc Clin Oncol 1996; 15: 477

    Google Scholar 

  15. Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891–6

    PubMed  CAS  Google Scholar 

  16. Huang SK, Lee K-D, Hong K, et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52: 5135–43

    PubMed  CAS  Google Scholar 

  17. Huang SK, Mayhew E, Gilani S, et al. Pharmacokinetics and therapeutics of sterically stabilised liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774–81

    PubMed  CAS  Google Scholar 

  18. Vaage J, Loftus T, Donovan D, et al. Tumor distribution of Doxil® and doxorubicin HCl visualized by laser confocal microscopy in animal models [abstract no. 1487]. Proc Am Soc Clin Oncol 1996; 14: 471

    Google Scholar 

  19. Vaage J, Barberá-Guillem E, Abra R, et al. Tissue distribution and therapeutic effects of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73: 1478–84

    Article  PubMed  CAS  Google Scholar 

  20. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93

    PubMed  CAS  Google Scholar 

  21. Goren D, Horowitz AT, Zalipsky S, et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996; 74: 1749–56

    Article  PubMed  CAS  Google Scholar 

  22. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 1995; 83: 1029–37

    Article  PubMed  CAS  Google Scholar 

  23. Northfelt DW. Stealth® liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi’s sarcoma (AIDSKS) lesions than to normal skin [abstract no. 5]. Proc Am Soc Clin Oncol 1994; 13: 51

    Google Scholar 

  24. Vaage J, Donovan D, Mayhew E. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72: 3671–5

    Article  PubMed  CAS  Google Scholar 

  25. Williams SS, Alosco TR, Mayhew E, et al. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993; 73: 1478–84

    Google Scholar 

  26. Sakakibara T, Fang-an C, Hisahi K, et al. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 1996; 56: 3743–6

    PubMed  CAS  Google Scholar 

  27. Vaage J, Loftus T, Uster PS, et al. Tumor uptake of doxorubicin in polyetheylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Brit J Cancer 1997; 75: 482–6

    Article  PubMed  CAS  Google Scholar 

  28. Vaage J, Donovan D, Mayhew E, et al. Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer 1993; 54: 959–64

    Article  PubMed  CAS  Google Scholar 

  29. Vaage J, Mayhew E, Lasic D, et al. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer 1992; 51: 942–8

    Article  PubMed  CAS  Google Scholar 

  30. Stürzl M, Zietz C, Eisenburg B, et al. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: clinical, histological and cell biological evaluation. Res Virol 1994; 145: 261–9

    Article  PubMed  Google Scholar 

  31. Legha SS, Benjamin RS, Mackay B, et al. Reduction of cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9

    PubMed  CAS  Google Scholar 

  32. Workman P. Infusional anthracyclines: is slower better? If so why? Ann Oncol 1992; 3: 591–4

    PubMed  CAS  Google Scholar 

  33. Cohen P, Gill PS, Wernz J, et al. Absence of cardiac toxicity in patients who received 3600 mg/m2 of liposomal encapsulated daunorubicin (DaunoXome®) [abstract no. 761]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Vol. 16. 1997 May 17–20: Denver, 217a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sharet Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel

    A. Gabizon

  2. SEQUUS Pharmaceuticals Inc., Menlo Park, California, USA

    F. Martin

Authors
  1. A. Gabizon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gabizon, A., Martin, F. Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin. Drugs 54 (Suppl 4), 15–21 (1997). https://doi.org/10.2165/00003495-199700544-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199700544-00005

Keywords

Search

Navigation